Table 5. Detailed analysis of HCC patient cohorts given in table 3 in regard to TGF-β1 and TGF-β2 up- and down-regulation.

TGF-β1	N°patients Up-Reg.	N°patients Down-Reg.	% patients Up	% patients Down	%patients not Significant	Mean Log2, Fold Change Up	Mean Log2, Fold Change Down
GSE1898	41	7	45,05	7,69	47,25	1,16	−0,66
GSE5975 EpCAM negative	65	33	45,77	23,24	30,99	1,26	−1,34
iCOD	16	26	11,43	18,57	70	1,45	−1,04
GSE50579	26	5	65	12,5	22,5	1,69	−1,78
GSE4024/GSE1898	61	10	42,96	7,04	50	1,02	−0,71

TGF-β2	N°patients Up-Reg.	N°patients Down-Reg.	% patients Up	% patients Down	%patients not Significant	Mean Log2, Fold Change Up	Mean Log2, Fold Change Down
GSE1898	23	1	25,27	1,1	73,63	0,79	−0,60
GSE5975 EpCAM negative	7	83	4,93	58,45	63,38	0,91	−0,95
GSE5975 EpCAM positive	7	36	7,45	38,3	54,26	0,68	−0,86
iCOD	27	9	19,29	6,43	74,29	1,38	−1,16
GSE50579	29	4	72,5	10	17,5	1,76	−1,01

Only those cohorts with significant p-values for the respective genes are used for this analysis, thus excluding TGF-β1 regulation in the GSE5975 EpCAM positive and GSE 14520 cohort as well as TGF-β2 in the GSE4024/GSE1898 and GSE 14520 cohort (see Table 4).